Denali Therapeutics Q1 EPS $(0.68) Beats $(0.70) Estimate
Portfolio Pulse from Benzinga Newsdesk
Denali Therapeutics reported Q1 earnings with losses of $(0.68) per share, surpassing the analyst consensus estimate of $(0.70) and marking a 15% improvement over last year's $(0.80) per share loss.
May 07, 2024 | 8:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Denali Therapeutics reported a smaller-than-expected loss per share in Q1, showing improvement over the previous year.
Beating EPS estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. The improvement over the previous year's losses further strengthens the positive outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100